School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Tarsus Pharmaceuticals, Inc. TARS

Healthcare · Biotechnology

$73.16last close 2026-10-09 · market cap $3.42B · delayed data

Trailing returns

1M-11.61%
3M+14.06%
6M+1.01%
1Y+3.95%
5Y+197.64%

Basis: Adjusted daily closes.

What it does

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.

Open TARS in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies